New Zealand markets closed

Dyne Therapeutics, Inc. (DYN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.86+0.21 (+0.89%)
At close: 04:00PM EDT
23.68 -0.18 (-0.75%)
After hours: 06:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.65
Open23.53
Bid23.85 x 200
Ask23.92 x 400
Day's range23.11 - 24.21
52-week range6.40 - 30.27
Volume973,256
Avg. volume1,412,517
Market cap2.056B
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
EPS (TTM)-3.95
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est37.75
  • GlobeNewswire

    Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

    WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox’s acce

  • GlobeNewswire

    Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

    WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024

  • GlobeNewswire

    Dyne Therapeutics Announces CEO Transition

    John Cox John Cox, President and CEO of Dyne Therapeutics - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive off